This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
South State (SSB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
SSBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, O-I Glass (OI)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
OIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
AnaptysBio, Inc. (ANAB) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ANABPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: DICE Up on Study Data, GILD, BIIB's Updates & More
by Zacks Equity Research
Regulatory and pipeline updates from DICE and RIGL are the key highlights from the biotech sector during the past week.
BIIBPositive Net Change GILDPositive Net Change VRTXNegative Net Change RIGLPositive Net Change
biotechnology biotechs pharmaceuticals
Gilead (GILD) Trodelvy Label Expansion sBLA Gets Priority Review
by Zacks Equity Research
Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.
GSKPositive Net Change DVAXPositive Net Change GILDPositive Net Change BOLTPositive Net Change
biotechnology biotechs
Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv
by Zacks Equity Research
Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.
NVSPositive Net Change DVAXPositive Net Change CYTKPositive Net Change BOLTPositive Net Change
biotechnology biotechs
Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs
by Zacks Equity Research
Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.
DVAXPositive Net Change LLYNegative Net Change RIGLPositive Net Change BOLTPositive Net Change
biotechnology biotechs
Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?
by Zacks Equity Research
Gilead (GILD) is having a good run despite the volatility on a string of positive updates.
GSKPositive Net Change NVSPositive Net Change GILDPositive Net Change BOLTPositive Net Change
biotechnology biotechs
Annovis (ANVS) Gains on FDA Authorization for AD Study
by Zacks Equity Research
Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).
BIIBPositive Net Change LLYNegative Net Change PRTAPositive Net Change ANVSPositive Net Change
biotechnology biotechs
Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract
by Zacks Equity Research
VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.
GSKPositive Net Change DVAXPositive Net Change VIRPositive Net Change BOLTPositive Net Change
biotechnology biotechs pharmaceuticals
Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug
by Zacks Equity Research
Provention (PRVB) collaborates with Sanofi for the commercialization of lead investigational drug candidate teplizumab.
SNYPositive Net Change DVAXPositive Net Change PRVBPositive Net Change BOLTPositive Net Change
biotechnology biotechs
The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics
by Zacks Equity Research
CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.
BEAMPositive Net Change SRPTPositive Net Change EDITPositive Net Change CRSPPositive Net Change
biotechnology
Zacks Market Edge Highlights: ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA
by Zacks Equity Research
ExxonMobil, Meta Platforms, UnitedHealth Group, Biogen and NVIDIA are part of the Zacks Market Edge article.
BIIBPositive Net Change UNHPositive Net Change XOMNegative Net Change NVDANegative Net Change METAPositive Net Change
biotechnology internet-content medical oil-energy semiconductor
Is Exelixis' (EXEL) Growth Story Likely to Continue?
by Zacks Equity Research
Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change EXELPositive Net Change
biotechnology
Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?
by Zacks Equity Research
Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology crispr
Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure?
by Zacks Equity Research
Bristol Myers (BMY) expects recent drug approvals to generate an incremental stream of revenues and combat competition for its key drugs.
BMYPositive Net Change MRKPositive Net Change AMGNPositive Net Change
biotechnology
Amylyx (AMLX) Secures the FDA's Approval for ALS Drug
by Zacks Equity Research
Amylyx (AMLX) obtains the FDA's approval for its oral, fixed-dose combination therapy for treating adults with amyotrophic lateral sclerosis (ALS) after a few roadblocks.
SNYPositive Net Change DVAXPositive Net Change AMLXPositive Net Change BOLTPositive Net Change
biotechnology biotechs pharmaceuticals
Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates
by Zacks Equity Research
Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.
REGNPositive Net Change SNYPositive Net Change BIIBPositive Net Change VRTXNegative Net Change IONSPositive Net Change
biotechnology biotechs pharmaceuticals
Toro (TTC) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
TTCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology bitcoin blockchain cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data
by Ekta Bagri
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
BIIBPositive Net Change RHHBYPositive Net Change LLYNegative Net Change PRTAPositive Net Change
biotechnology biotechs pharmaceuticals
Biogen's (BIIB) Lecanemab Meets Goal in Alzheimer's Study
by Zacks Equity Research
Biogen (BIIB) and Eisai's Clarity AD study showed that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of clinical decline on the CDR-SB scale by 27% compared to placebo.
SNYPositive Net Change BIIBPositive Net Change RHHBYPositive Net Change LLYNegative Net Change
biotechnology
Bet on These 4 Biotech Stocks With Bright Prospects
by Ekta Bagri
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.
DVAXPositive Net Change AGENPositive Net Change CVACPositive Net Change IMCRPositive Net Change
biotechnology biotechs
Atea (AVIR) Dengue Candidate Gets Fast Track Designation
by Zacks Equity Research
Atea Pharmaceuticals (AVIR) obtains Fast Track Designation in the United States for AT-752 for the treatment of dengue virus infection.
DVAXPositive Net Change MRKPositive Net Change AVIRPositive Net Change BOLTPositive Net Change
biotechnology biotechs pharmaceuticals
Intercept (ICPT) Stock Gains 13% in 3 Months: Here's Why
by Zacks Equity Research
Intercept (ICPT) gains 13% in the past three months on positive regulatory and pipeline updates.
ICPTPositive Net Change VKTXPositive Net Change BOLTPositive Net Change
biotechnology biotechs pharmaceuticals
Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More
by Zacks Equity Research
Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.
ALNYNegative Net Change BMYPositive Net Change GILDPositive Net Change ELOXNo Net Change
biotechnology biotechs